2015 Antineoplastics

2. ANTIBODIES and FUSION PROTEINS

TARGET
DRUG
USE
CD20
RITUXIMAB
IBRITUMOMAB (90Y)
TOSITUMOMAB (131I)
CD33
GEMTUZUMAB
acute myeloid leukemia (AML)
CD52
ALEMTUZUMAB
B-cell chronic lymphocytic leukemia (B-CLL)
EGFR
CETUXIMAB
PANITUMUMAB
metastatic colon cancer
17-1A
EDECOLOMAB
colon cancer
HER2
TRASTUZUMAB
metastatic breast cancer
VEGF
BEVACIZUMAB
discussed under antiangiogenesis
Email: Dr. Janet Fitzakerley | ©2015 University of Minnesota Medical School Duluth | Last modified: 11-apr-15 9:39 AM